相关实验视频

Updated: Jan 6, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

综合性检查 Hypericum perforatum 和高素:通过网络药理学和基因表达分析发现的抗肥胖机制

Hilal Büşra Tokgöz^1,2, Filiz Altan³

¹Molecular Biology and Genetics Department, Muğla Sıtkı Koçman University, Muğla, Turkey.

Plant foods for human nutrition (Dordrecht, Netherlands)

|November 14, 2025

概括

圣约翰草 (Hypericum perforatum) 提取物及其化合物高素显示出抗肥胖的潜力. 它们针对参与脂肪积累,胰岛素抵抗和炎症的关键途径,支持它们作为天然治疗剂的使用.

科学领域:

植物化学植物化学
药理学药理学是指药理学的学科.
生物信息学是一种生物信息学.

背景情况:

胡卜 (Hypericum perforatum) 传统上用于代谢和炎症疾病.
它的抗抑郁作用是众所周知的,但它在肥胖管理中的作用是不充分研究的.
这项研究调查了H. perforatum提取物和hypericin的抗肥胖潜力.

研究的目的:

为了评估H. perforatum提取物和hypericin的抗肥胖作用.
探索它们对脂肪生成,炎症,胰岛素信号和线粒体功能障碍的影响.
通过体外和体方法阐明潜在的分子机制.

主要方法:

在体外研究中,使用3T3-L1预adipocytes治疗过素或H. perforatum提取物.
测试包括MTT,油红色O染色,RT-qPCR和ELISA.
在 silico 分析中涉及目标预测,网络分析,分子对接和通路丰富 (GO,KEGG).

主要成果:

H. perforatum 提取物和高素调节了脂肪生成和减少了脂质积累.
它们调节了参与胰岛素敏感性和炎症的基因和蛋白质.
分子对接揭示了超素与PPAR-γ,IRS-1,FABP4和TNF-α等点的强烈结合,生物信息分析表明PPAR信号通路的激活.

结论:

H. perforatum 和高素显示出多个目标的抗肥胖作用.
这些效应通过对代谢,炎症和线粒体路径的调节来调节.
这些发现支持H. perforatum和hypericin作为肥胖管理的天然治疗剂的潜力.

关键词:

这种植物名为Hypericum perforatum.增脂生殖是一种增脂的过程.过高氨酸的使用方法炎症炎症是一种炎症.分子对接是分子对接.网络药理学网络药理学

更多相关视频

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...